Type 2 diabetes mellitus
Conditions
Interventions
investigational material(s)
Generic name etc : Trelagliptin 100 mg + Alogliptin 25 mg
INN of investigational material : Trelagliptin, Alogliptin
Therapeutic category code : 396 Antidiabetic agents
Dos
Sponsors
TAKEDA PHARMACEUTICAL COMPANY LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Participants who have been diagnosed with type 2 diabetes mellitus. 2. Participants who are being treated with any of the following DPP-4 inhibitors for at least 8 weeks prior to the time of informed consent (Week 0). - Sitagliptin : 50 mg once daily - Alogliptin : 25 mg once daily - Linagliptin : 5 mg once daily - Teneligliptin : 20 mg once daily - Saxagliptin : 5 mg once daily 3. Participants who were judged by the investigators possible to change the treatment from daily dosing of DPP-4 inhibitor shown in Inclusion Criteria 2 to study drug trelagliptin 100 mg or alogliptin 25 mg. 4. Participants whose glycosylated hemoglobin (HbA1c) value measured within 8 weeks prior to the time of informed consent (Week 0) is below 10.0%. 5. Participants who responded to Diabetes Treatment Satisfaction Questionnaire (DTSQ) at the time of informed consent (Week 0). 6. Participants who were judged by the investigators capable to understand the contents of this clinical research and comply with them. 7. Participants who are able to sign and date the Informed Consent Form before any clinical research procedure begins. 8. Participants who are at least 20 years old at the time of giving the consent. 9. Participants who are classified as outpatients.
Exclusion criteria
Exclusion criteria: 1. Participants who have a history of taking once-weekly dosing of DPP-4 inhibitor (trelagliptin or omarigliptin). 2. Participants who are being treated with drugs other than those for once-daily oral dosing for the purpose of treatment of chronic complication (for example, "BENET Tablets 75 mg", a therapeutic agent for osteoporosis which is administered once monthly). 3. Participants who are being treated with twice-daily dosing of DPP-4 inhibitor (vildagliptin or anagliptin). 4. Participants who are being treated with anti-diabetic fixed-dose combination pill contained a DPP-4 inhibitor. 5. Participants with moderate or severe renal impairment (for example, participant whose estimated glomerular filtration rate (eGFR) is below 60 mL/min/1.73m^2). 6. Participants for whom blood sugar control by insulin preparations is desired (for example, participants with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, or serious trauma before or after surgery). 7. Participants who have a history of hypersensitivity or allergy to DPP-4 inhibitor. 8. Participants with serious heart disease, cerebrovascular disorder, or participants with serious disease in the pancreas, blood, etc. 9. Participants with unstable proliferative diabetic retinopathy. 10. Participants with malignant tumor. 11. Participants who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant. 12. Participants participating in other clinical studies. 13. Participants who have been determined as inappropriate participants by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy Number of Participants by their Treatment Preference Using Standardized Questions at the End of Treatment Period Time Frame: At Week 16 Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. Participants selected one choice from the following 4 choices; either once-weekly DPP-4 inhibitor or daily DPP-4 inhibitor, once-weekly DPP-4 inhibitor, daily DPP-4 inhibitor, neither once-weekly DPP-4 inhibitor nor daily DPP-4 inhibitor. Reported data was the number of participants with a choice of either trelagliptin (a once-weekly DPP-4 inhibitor) or alogliptin (a once-daily DPP-4 inhibitor), trelagliptin, alogliptin, neither trelagliptin nor alogliptin. | — |
Secondary
| Measure | Time frame |
|---|---|
| efficacy Number of Participants by their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors Time Frame: At Week 16 Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. The preference of drug therapy was categorized by background factors like age (years), gender, height (cm), weight (kg), BMI (kg/m^2), duration of diabetes (years), work status, alcohol intake history, smoking habits, experience of educational hospitalization on DM, presence of cohabiter, percentage of compliance with DPP-4 inhibitors during 4-weeks before the start of treatment period, number of oral drugs per day at the beginning of treatment period (excluding investigational drug), complication of metabolic syndrome, percentage of HbA1c (NGSP is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at the time of informed consent. efficacy Number of Participants by their Treatment Preference Using Standardized Questions at the End of Treatment Period by Background Factors (T-A Administered Group) Time Frame: At Week 16 Participants answered standardized questions about their preference of drug therapy for Type 2 Diabetes Mellitus. The preference of drug therapy was categorized by background factors like age (years), gender, height (cm), weight (kg), BMI (kg/m^2), duration of diabetes (years), work status, alcohol intake history, smoking habits, experience of educational hospitalization on DM, presence of cohabiter, percentage of compliance with DPP-4 inhibitors during 4-weeks before the start of treatment period, number of oral drugs per day at the beginning of treatment period (excluding investigational drug), complication of metabolic syndrome, percentage of HbA1c (NGSP is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at the time of informed consent. efficacy Number of Partic | — |
Countries
Japan
Outcome results
None listed